Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.
Current Team (7)Update
Chief Medical Officer
Vice President, Research
Chief Financial Officer
Co-Founder and Director
Executive Vice President of Business Development
President and CEO
Senior Director, Finance and Corporate Controller
Funding Rounds (5) - $46.2MUpdate
Board Members and Advisors (14)Update
Third Rock Ventures invests in transformational life science companies that show high growth...
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Emerging Technology VC
Ysios Capital is one of the first independent venture capital firms in Spain providing private...
Lighthouse Capital Partners is the leading venture debt firm, providing capital to early- and...
100 Beaver St.
Waltham, MA 02453
135 Beaver St., Suite 309
Waltham, MA 02452